IFITM4P and neoplasm: IFITM4P enhances the interaction of KDM5A with the PTEN promoter, resulting in reduced transcription of PTEN and upregulated PD-L1 expression, thus activating the therapeutic sensitivity of PD-1 in the nucleus of tumor cells (121).